- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02982915
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty (HERA)
November 3, 2022 updated by: Longeveron Inc.
Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A pilot phase will consist of a 3 subject safety run-in, followed by 20 subject randomized phase to evaluate influenza vaccine response at 1 week and 4 weeks post infusion of Lomecel-B (Formerly LMSCs).
This will be followed by a double-blinded, randomized, placebo-controlled phase.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Clinical Research of South Florida
-
Fort Myers, Florida, United States, 33912
- Clinical Physiology Associates
-
Miami, Florida, United States, 33136
- University of Miami
-
Miami, Florida, United States, 33176
- Vista Health Research
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins University
-
Rockville, Maryland, United States, 20850
- Optimal Research LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
63 years to 88 years (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- be willing and able to provide written informed consent and comply with all procedures required by the protocol.
- be 65 - 90 years of age at the time of signing the Informed Consent Form.
- have a diagnosis of Aging Frailty, with a score of 4 to 7 using the Canadian Frailty Scale.
- have a six-minute walk test (6MWT) distance of 200m - 400m for each of 2 trials, and the 2 trials must be within 15% of each other.
- have total bilirubin between 0.3 - 1.9 mg/dL.
Exclusion Criteria:
- be unwilling or unable to perform any of the assessments required by the Protocol.
- score ≤24 on the Mini Mental State Examination (MMSE).
- have previously received current year's flu-vaccine.
- have any contraindication to receiving a vaccine.
- have a Hemoglobin A1c (HbA1c) level >9.0%.
- be diagnosed with malignancy (subjects without a recurrence in the last 2.5 years will be allowed) except curatively-treated basal cell carcinoma, melanoma in situ, or cervical carcinoma.
- have a condition that projected to limit the life-expectancy to ≤1 year.
- have autoimmune disease (e.g., rheumatoid arthritis).
- be using medication(s) known to alter immune response, e.g., high-dose corticosteroids.
- have HIV, AIDS, or other immunodeficiency.
test positive for hepatitis B virus
- If the subject tests positive for anti-HBc or anti-HBs, they must be receiving treatment for Hepatitis B virus prior to infusion and remain on treatment throughout the study.
- test positive for viremic hepatitis C, HIV1, HIV2, or syphilis.
- have a resting blood oxygen saturation of <93% (measured by pulse oximetry).
- be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception.
- have documented current substance and/or alcohol abuse.
- have known allergies to latex or eggs.
- have a known hypersensitivity to dimethyl sulfoxide (DMSO).
- be an organ transplant recipient (other than corneal, bone, skin, ligament, or tendon transplant).
- be actively listed (or expected to be listed) for transplant of any organ (other than corneal, bone, skin, ligament, or tendon transplant).
have any clinically important abnormal screening laboratory values, including but not limited to:
- hemoglobin <10.0 g/dL.
- white blood cell count < 2500/mm3.
- platelets < 100,000/mm3.
- prothrombin time/international normalized ratio (PT/INR) ˃ 1.5 not due to a reversible cause (i.e. Coumadin).
- aspartate transaminase, alanine transaminase, or alkaline phosphatase ˃ 2 times upper limit of normal.
- have a sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.
- have any serious illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study, or that may compromise the validity of the study.
- be currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that the subject actively participates in this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pilot Phase- Cohort A
Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
|
Intravenously delivered
Other Names:
Intramuscular injection
|
Experimental: Pilot Phase Cohort B & C
Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
|
Intravenously delivered
Other Names:
Intramuscular injection
|
Experimental: Double-Blind,Randomized,Placebo Phase
2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
|
Intravenously delivered
Other Names:
Intramuscular injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:
Time Frame: 30 days after infusion
|
|
30 days after infusion
|
The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays.
Time Frame: Baseline Visit, Vaccination Visits, Weeks 1, 2, 4, Month 6 and Month 12 Follow-Up Visits.
|
Measurements of validated hemagglutination inhibition (HAI) assays at follow up visits.
|
Baseline Visit, Vaccination Visits, Weeks 1, 2, 4, Month 6 and Month 12 Follow-Up Visits.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline between the LMSC and placebo cohorts as assessed by plasma cytokine levels:
Time Frame: Baseline, month 6 and month 12 after infusion
|
Plasma levels of interleukins measured in pg/mL.
|
Baseline, month 6 and month 12 after infusion
|
Differences in rate of decline from Aging Frailty
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in Clinical Frailty rating
|
Baseline, month 6 and month 12 after infusion
|
Assessed by the Falls Efficacy Scale-International and Performance Oriented Mobility Assessment
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in risk of falling
|
Baseline, month 6 and month 12 after infusion
|
PROMIS Short Form 20a questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
PROMIS Mobility questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
PROMIS Upper Extremity questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
Short Form 36 questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
IIEF questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
SQOL-F questionnaire
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change in subject quality of life as assessed by participant-reported outcomes.
|
Baseline, month 6 and month 12 after infusion
|
Death from any cause
Time Frame: Within 12 months after infusion
|
Number of participants that die from any cause while enrolled on the trial and after being treated with LMSCs.
|
Within 12 months after infusion
|
Falls Efficacy Scale-International (FES-I)
Time Frame: Baseline, month 6 and month 12 after infusion
|
Change by participant-reported outcomes.
Minimum 16 (no concern about falling) to maximum 64 (severe concern about falling)
|
Baseline, month 6 and month 12 after infusion
|
Changes from baseline between the LMSC and placebo cohorts as assessed by B & T cell levels:
Time Frame: Baseline, month 6 and month 12 after infusion
|
Plasma levels of B & T Cells.
|
Baseline, month 6 and month 12 after infusion
|
Rate of decline in Aging Frailty status as assessed by the 6 minute walk test
Time Frame: Baseline, month 6 and month 12 after infusion
|
Distance in meters walked in 6 minutes
|
Baseline, month 6 and month 12 after infusion
|
Rate of decline in Aging Frailty status as assessed by the Short Physical Performance Battery (SPPB)
Time Frame: Baseline, month 6 and month 12 after infusion
|
Short Physical Performance Battery Assessment
|
Baseline, month 6 and month 12 after infusion
|
Rate of decline in Aging Frailty status as assessed by the Tinetti POMA Test
Time Frame: Baseline, month 6 and month 12 after infusion
|
TInetti POMA assessment
|
Baseline, month 6 and month 12 after infusion
|
Rate of decline in Aging Frailty status as assessed by the Weight Loss
Time Frame: Baseline, month 6 and month 12 after infusion
|
Weigh measurements at visits
|
Baseline, month 6 and month 12 after infusion
|
Rate of decline in Aging Frailty status as assessed by the Handgrip Test
Time Frame: Baseline, month 6 and month 12 after infusion
|
Handgrip strength via dynamometer.
|
Baseline, month 6 and month 12 after infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2016
Primary Completion (Actual)
September 1, 2021
Study Completion (Actual)
September 1, 2022
Study Registration Dates
First Submitted
November 17, 2016
First Submitted That Met QC Criteria
December 1, 2016
First Posted (Estimate)
December 6, 2016
Study Record Updates
Last Update Posted (Actual)
November 4, 2022
Last Update Submitted That Met QC Criteria
November 3, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00-0000-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging Frailty
-
University of AlbertaAlberta Health services; Glenrose FoundationActive, not recruitingHealthy | Frail Elderly Syndrome | Frailty | Healthy Aging | Frailty Syndrome | Aging Problems | Aging Disorder | Pre-FrailtyCanada
-
The Opole University of TechnologyRecruitingPrevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People (FRAILPOL)Frail Elderly Syndrome | Frailty | Aging | Frailty Syndrome | Aging Problems | Fragility | Aging Well | Aging DisorderPoland
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Shanghai East HospitalCompleted
-
Cellcolabs Clinical SPV LimitedPDC-CRORecruitingAging FrailtyUnited Arab Emirates
-
University of PennsylvaniaCompleted
-
University of SouthamptonTameside Hospital NHS Foundation Trust; Bournemouth University; Southern Health...Active, not recruitingOlder People | Frailty in AgingUnited Kingdom
-
Haukeland University HospitalNot yet recruitingFrail Elderly Syndrome | Frailty | Aging | Frailty SyndromeNorway
-
Chinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
Wake Forest University Health SciencesActive, not recruiting
Clinical Trials on Longeveron Mesenchymal Stem Cells (LMSCs)
-
Longeveron Inc.Active, not recruiting
-
Longeveron Inc.Active, not recruitingCovid19 | ARDS, HumanUnited States
-
Longeveron Inc.CompletedAging FrailtyUnited States
-
Longeveron Inc.CompletedAlzheimer's DiseaseUnited States
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Hospital ZnojmoUnknown
-
National Research Center for Hematology, RussiaUnknownRelapse | Graft-versus-host DiseaseRussian Federation
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom